Related Experiment Video

Updated: May 17, 2026

Assays for Validating Histone Acetyltransferase Inhibitors
09:11

Assays for Validating Histone Acetyltransferase Inhibitors

Published on: August 6, 2020

Histone deacetylase inhibitors: a patent review (2009 - 2011)

Vincenzo Carafa1, Marco Miceli, Lucia Altucci

  • 1Seconda Università degli Studi di Napoli, Dipartimento di Patologia Generale, Italy.

Expert Opinion on Therapeutic Patents
|October 26, 2012
PubMed
Abstract

Insights

Histone deacetylase inhibitors (HDACis) show promise as anti-cancer agents by modulating gene expression and inducing tumor cell death. Research is expanding to explore HDACis for treating various non-cancer diseases as well.

Area of Science:

  • Molecular Biology
  • Pharmacology
  • Oncology

Background:

  • Histone deacetylases (HDACs) are key regulators of gene expression implicated in numerous diseases.
  • HDAC inhibitors (HDACis) modulate transcriptional activity, offering therapeutic potential.
  • HDACis induce anti-tumor effects like cell cycle arrest, differentiation, and apoptosis.

Purpose of the Study:

  • To review current knowledge and molecular mechanisms of HDAC inhibitors.
  • To survey recent patents related to HDAC inhibitors from 2009-2011.

Main Methods:

  • Literature review
  • Patent analysis

Main Results:

  • Identification of diverse HDAC inhibitor structures.
  • Expansion of HDAC inhibitor applications beyond cancer.

Conclusions:

  • HDAC inhibitors are emerging as potential treatments for solid and hematological malignancies.
  • Non-cancer diseases like neurodegeneration, metabolic, inflammatory, autoimmune, infectious, and cardiovascular disorders are potential targets for HDACi therapy.
  • A significant increase in global patent applications for HDAC inhibitors reflects their growing therapeutic importance.

More Related Videos

Simultaneous Measurement of HDAC1 and HDAC6 Activity in HeLa Cells Using UHPLC-MS09:20

Simultaneous Measurement of HDAC1 and HDAC6 Activity in HeLa Cells Using UHPLC-MS

Published on: August 10, 2017

An Acetyl-Click Chemistry Assay to Measure Histone Acetyltransferase 1 Acetylation05:44

An Acetyl-Click Chemistry Assay to Measure Histone Acetyltransferase 1 Acetylation

Published on: January 26, 2024

Related Concept Videos

Spreading of Chromatin Modifications02:25

Spreading of Chromatin Modifications

The histone proteins in the nucleosomes are post-translationally modified (PTM) to increase or decrease access to DNA. The commonly observed PTMs are methylation, acetylation, phosphorylation, and ubiquitination of lysine amino acids in the histone H3 tail region. These histone modifications have specific meaning for the cell. Hence, they are called "histone code". The protein complex involved in histone modification is termed as "reader-writer" complex.
Writers
The writer is an enzyme that can...
Histone Modification02:32

Histone Modification

The histone proteins have a flexible N-terminal tail extending out from the nucleosome. These histone tails are often subjected to post-translational modifications such as acetylation, methylation, phosphorylation, and ubiquitination. Particular combinations of these modifications form “histone codes” that influence the chromatin folding and tissue-specific gene expression.
Acetylation
The enzyme histone acetyltransferase adds acetyl group to the histones. Another enzyme, histone deacetylase,...
Histone Modification02:32

Histone Modification

The histone proteins have a flexible N-terminal tail extending out from the nucleosome. These histone tails are often subjected to post-translational modifications such as acetylation, methylation, phosphorylation, and ubiquitination. Particular combinations of these modifications form “histone codes” that influence the chromatin folding and tissue-specific gene expression.
Acetylation
The enzyme histone acetyltransferase adds acetyl group to the histones. Another enzyme, histone deacetylase,...
FDA Approved Drugs: Changes to Approved Drugs01:26

FDA Approved Drugs: Changes to Approved Drugs

Post-approval, manufacturers may modify an approved new or generic drug product. Such modifications can encompass alterations in the Active Pharmaceutical Ingredient (API), manufacturing process, formulation, batch size, manufacturing site, and container closure system (FDA Guidance for Industry, April 2004). Often, a drug product may undergo multiple changes.These modifications require careful evaluation to determine their potential impact on the drug product's identity, strength, quality,...
Histone Variants at the Centromere02:30

Histone Variants at the Centromere

Histone variants are the histone proteins with structural and sequence variations. These variants may be regarded as “mutant” forms that replace their canonical histone counterparts in the nucleosomes. Specific post-translational modifications on the histone variants enable further chromatin complexity and regulate tissue-specific gene expression. The most common histone variants are from histone H2A, H2B, and linker histone H1 families. However, several variants of histone H3 variants are also...
Eukaryotic Transcription Inhibitors01:52

Eukaryotic Transcription Inhibitors

Certain biochemical processes, such as embryonic development and cell growth regulation, depend on the repression of specific genes. DNA binding proteins known as eukaryotic transcription inhibitors regulate the repression of gene expression in eukaryotes. The presence of these inhibitors at the required location and time in the cell is triggered by the presence of hormones and additional signals from other cells.
Eukaryotic transcription inhibitors usually contain two distinct domains, a DNA...